Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 21, 2015; 21(39): 11168-11178
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11168
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11168
Figure 6 Plasma interleukin-8 levels in pancreatic ductal adenocarcinoma patients receiving chemoimmunotherapy.
A: Plasma interleukin (IL)-8 levels in 7 patients during treatment; B: Comparison of plasma IL-8 levels prior to treatment between super-responders [overall survival (OS) ≥ 1 year] and nonsuper-responders (OS < 1 year); C: Comparison of plasma IL-8 levels in super-responders prior to treatment and post-vaccination; D: Comparison of plasma IL-8 levels after 5 vaccinations in nonsuper-responders and super-responders after 5, 10, 15, 20, and 25 vaccinations. The values are expressed as means ± SD. aP < 0.05.
- Citation: Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sugiyama H, Sumiyama K, Ohkusa T, Koido S. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J Gastroenterol 2015; 21(39): 11168-11178
- URL: https://www.wjgnet.com/1007-9327/full/v21/i39/11168.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i39.11168